P. Stoy

发表

Advances in Lead Generation.

Joerg Holenz, P. Stoy, 2019, Bioorganic & medicinal chemistry letters.

Discovery of Pyrrolidine Sulfonamides as Selective and Orally Bioavailable Antagonists of Transient Receptor Potential Vanilloid-4 (TRPV4).

Carl A. Brooks, D. Holt, D. Behm, 2018, Journal of medicinal chemistry.

Identification of a Human Whole Blood-Based Endothelial Cell Impedance Assay for Assessing Clinical TRPV4 Target Engagement Ex Vivo

D. Sprecher, N. Goyal, T. Roethke, 2020 .

Cycloadditions of nonstabilized 2-azaallyllithiums (2-azaallyl anions) and azomethine ylides with alkenes: [3+2] Approaches to pyrrolidines and application to alkaloid total synthesis

W. H. Pearson, P. Stoy, 2003 .

Inhibition of the Cardiomyocyte-Specific Kinase TNNI3K Limits Oxidative Stress, Injury, and Adverse Remodeling in the Ischemic Heart

A. P. Graves, M. Madesh, G. Gatto, 2013, Science Translational Medicine.

Quinolines as extremely potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction.

J. Macor, J. Krupinski, A. Watson, 2004, Bioorganic & Medicinal Chemistry Letters.

Total synthesis of the Kopsia lapidilecta alkaloid (+/-)-lapidilectine B.

W. H. Pearson, Y. Mi, P. Stoy, 2001, Journal of the American Chemical Society.

The discovery of novel, potent and selective PDE5 inhibitors.

J. Macor, J. Krupinski, A. Watson, 2001, Bioorganic & medicinal chemistry letters.

Azomethine ylides from tin-substituted cyclic carbinol amides: a new route to highly substituted pyrrolizidines.

W. H. Pearson, P. Stoy, Amber L. Dietz, 2004, Organic Letters.

Total synthesis of the Kopsia lapidilecta alkaloid (+/-)-lapidilectine B.

W. H. Pearson, I. Lee, Y. Mi, 2004, The Journal of organic chemistry.

Chlorinated Solvents: Their Advantages, Disadvantages, and Alternatives in Organic and Medicinal Chemistry.

H. Sneddon, P. Stoy, A. Jordan, 2020, Chemical reviews.

A three-component, one-pot synthesis of indolizidines and related heterocycles via the [3+2] cycloaddition of nonstabilized azomethine ylides.

W. H. Pearson, Y. Mi, P. Stoy, 2004, The Journal of organic chemistry.

The Synthesis of 9,10‐Dihydro‐9,10‐(Methaniminomethano)Anthracene and N‐Protected Derivatives Via Double Reductive Amination

W. H. Pearson, P. Stoy, J. Rush, 2004 .

Fluorous affinity purification of oligonucleotides.

A. Sercel, D. Berry, W. H. Pearson, 2005, The Journal of organic chemistry.

Design and Optimization of an Acyclic Amine Series of TRPV4 Antagonists by Electronic Modulation of Hydrogen Bond Interactions.

D. Holt, R. Rivero, A. Shu, 2020, Journal of medicinal chemistry.

Identification of a Human Whole Blood–Based Endothelial Cell Impedance Assay for Assessing Clinical Transient Receptor Potential Vanilloid 4 Target Engagement Ex Vivo

D. Behm, K. Thorneloe, D. Sprecher, 2020, The Journal of Pharmacology and Experimental Therapeutics.

Discovery of GSK2798745: A Clinical Candidate for Inhibition of Transient Receptor Potential Vanilloid 4 (TRPV4).

Carl A. Brooks, D. Holt, D. Behm, 2019, ACS medicinal chemistry letters.

Improving the developability profile of pyrrolidine progesterone receptor partial agonists.

C. Duraiswami, N. Laping, Shawn P. Williams, 2010, Bioorganic & medicinal chemistry letters.

Identification of Diarylurea Inhibitors of the Cardiac-Specific Kinase TNNI3K by Designing Selectivity Against VEGFR2, p38α, and B-Raf.

D. Holt, A. P. Graves, L. Shewchuk, 2021, Journal of medicinal chemistry.

Inhibition of the Cardiomyocyte-Specific Kinase TNNI3K Limits Oxidative Stress, Injury, and Adverse Remodeling in the Ischemic Heart

M. Madesh, B. Lawhorn, K. Mallilankaraman, 2013, Science Translational Medicine.